Misleading de novo detection of serum anti-HLA-A3 antibodies in kidney recipients having received ATG before transplantation.
Anti-HLA antibody (Ab) monitoring is essential for the follow-up of transplant patients. However, it can be affected by drugs, especially Ab infused as a conditioning regimen for transplantation. ATG Fresenius, commonly used in this setting, is a polyclonal rabbit Ab raised against the Jurkat human T cell line (HLA-A3, 32; B7, 35). We report here the de novo detection by CDC and flow cytometry (Luminex) of anti-HLA-A3 Ab in the serum of kidney recipients treated with ATG Fresenius. The Ab, of rabbit origin, was detected in every assessable patient (n = 16), with the exception of the HLA-A3 recipients and/or recipients receiving an HLA-A3 graft, before becoming undetectable, at latest, at day 102 after transplantation. It is of major importance that transplantation monitoring laboratories bear in mind the possibility of therapeutic Ab detection when interpreting anti-HLA Ab results.
Masson
Emeline
E
INSERM, UMR 645, Université de Franche-Comté, EFS BFC, IFR 133, Besançon, France.
Devillard
Nadège
N
Chabod
Jacqueline
J
Yannaraki
Maria
M
Thevenin
Chantal
C
Tiberghien
Pierre
P
Rebibou
Jean-Michel
JM
D000328:Adult; D000818:Animals; D000906:Antibodies / Q000097:blood*; D000961:Antilymphocyte Serum / Q000009:adverse effects*; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D015791:HLA-A3 Antigen / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D011817:Rabbits; D019172:Transplantation Conditioning / Q000009:adverse effects*
D000906:Antibodies; D000961:Antilymphocyte Serum; D015791:HLA-A3 Antigen